|Mr. Indranil Dey||Pres, CEO & Director||181.61k||N/A||1964|
|Dr. Jason Cook||Chief Technology Officer||308.3k||N/A||1982|
|Mr. Kenneth R. Fisher CPA||Chief Financial Officer||N/A||N/A||1980|
|Mr. Edwin Rule||VP of Regulatory, Quality & Compliance||N/A||N/A||N/A|
|Mr. Kevin Vance||Chief Commercial Officer||N/A||N/A||1957|
|Mark W. Feinberg||Chief Medical Advisor||N/A||N/A||N/A|
|Dr. Mark W. Feinberg M.D.||Chief Medical Advisor||N/A||N/A||N/A|
Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. In addition, it develops biomarkers for detection of other diseases such as hsTNT/I for myocardial injury and NT-proBNP for cardiac heart failure. It has a license and supply agreement with Toray Industries, Inc. for making and distributing the protein detection chips. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Bluejay Diagnostics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.